US5556958A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Inactivation of pathogens in clinical samples
Assignee: Cerus Corp
•
Filing: 1994-06-03
•
Granted: 1996-09-17
•
Expires: 2014-06-03
Abstract
Abstract The present invention contemplates methods of decontaminating human fluids prior to processing in the clinical laboratory. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Inventors
- 👤 Peter G. Carroll
- 👤 Stephen T. Isaacs
- 👤 George D. Cimino
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 04:10
CPC Classifications
C; C07; C07D; C07D493/00; C07D493/02; C07D493/04; A; A61; A61L; A61L2/00; A61L2/02; B; B01; B01L; B01L7/00; B01L7/52; C07D311/00; C07D311/02; C07D311/04; C07D311/06; C07D311/08; C07D311/18; C07H; C07H21/00; C12; C12N; C12N15/00; C12N15/09; C12N15/10; C12P; C12P19/00; C12P19/26; C12P19/28; C12P19/30; C12P19/34; C12Q; C12Q1/00; C12Q1/68; C12Q1/6844; C12Q1/6848; C12Q1/6853; C12Q1/6876; C12Q1/70; C12Q1/701; C12Q1/702; C12Q1/703; A61L2103/00; A61L2103/05; A61L2103/09; Y; Y10; Y10S; Y10S435/00; Y10S435/80; Y10S435/81; Y10S530/00; Y10S530/827; Y10S530/829
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
127 words
A method of treating biological material intended for in vitro clinical testing, comprising: a) providing, in any order, i) a container containing one or more aminopsoralens; ii) a photoactivation device comprising a filter providing wavelength cutoffs at 320 nm, below which no irradiation is transmitted, and at 360 nm, above which no irradiation is transmitted; and iii) material intended for in vitro clinical testing suspected of being contaminated with a nucleic acid-containing pathogen; b) adding said material to said container; c) photoactivating said aminopsoralens under conditions such that said aminopsoralens are capable of modifying said nucleic acid of said nucleic acid-containing pathogen, so that said pathogen is inactivated, and; d) testing said material for the presence of a serum analyte, wherein said photoactivating preserves said serum analyte.
Claim 2
Independent Claim
127 words
A method of treating biological material intended for in vitro clinical testing, comprising: a) providing, in any order, i) a container containing one or more aminopsoralens; ii) a photoactivation device comprising a filter providing wavelength cutoffs at 320 nm, below which no irradiation is transmitted, and at 360 nm, above which no irradiation is transmitted; and iii) material intended for in vitro clinical testing suspected of being contaminated with a nucleic acid-containing pathogen; b) adding said material to said container; c) photoactivating said aminopsoralens under conditions such that said aminopsoralens are capable of modifying said nucleic acid of said nucleic acid-containing pathogen, so that said pathogen is inactivated, and; d) testing said material for the presence of a serum analyte, wherein said photoactivating preserves said serum analyte.
Claim 3
Dependent Claim
23 words
The method of claim 1, wherein the intensity of said irradiation received by said material is between 1 and 20 mW/cm 2 .
Claim 4
Dependent Claim
18 words
The method of claim 1, wherein said material comprises whole blood which comprises red blood cells and serum.
Claim 5
Dependent Claim
25 words
The method of claim 3, further comprising centrifuging said whole blood, prior to photoactivating said aminopsoralens, to separate said red blood cells from said serum.
Claim 6
Dependent Claim
10 words
The method of claim 1, wherein said aminopsoralen is 4'-aminomethyl-4,5',8-trimethylpsoralen.
Claim 7
Dependent Claim
10 words
The method of claim 1, wherein said aminopsoralen is 4'-aminomethyl-4,5'-dimethyl-8-methoxypsoralen.
Claim 8
Dependent Claim
10 words
The method of claim 1, wherein said aminopsoralen is radiolabeled-4'-aminomethyl-4,5'-dimethyl-8-methoxypsoralen.
Claim 9
Dependent Claim
10 words
The method of claim 1, wherein said aminopsoralen is biotinylated.
Claim 10
Dependent Claim
15 words
The method of claim 1, wherein said container is in part transparent to ultraviolet light.
Claim 11
Dependent Claim
13 words
The method of claim 9, wherein said container is a blood collection tube.
Claim 12
Independent Claim
142 words
A method of treating human serum intended for in vitro clinical testing, comprising: a) providing, in any order, i) a container containing human serum intended for in vitro clinical serum analyte testing suspected of being contaminated with a nucleic acid-containing viral pathogen; ii) a photoactivation device comprising a filter providing wavelength cutoffs at 320 nm, below which no irradiation is transmitted, and at 360 nm, above which no irradiation is transmitted; and iii) one or more aminopsoralens; b) adding said aminopsoralen to said human serum in said container; c) photoactivating said aminopsoralens with said photoactivation device under conditions such that said aminopsoralens are capable of modifying said nucleic acid of said nucleic acid-containing vital pathogen, so that said vital pathogen is inactivated, without causing damage to said clinical sample; and d) testing said human serum for the presence of a serum analyte.
Claim 13
Independent Claim
142 words
A method of treating human serum intended for in vitro clinical testing, comprising: a) providing, in any order, i) a container containing human serum intended for in vitro clinical serum analyte testing suspected of being contaminated with a nucleic acid-containing viral pathogen; ii) a photoactivation device comprising a filter providing wavelength cutoffs at 320 nm, below which no irradiation is transmitted, and at 360 nm, above which no irradiation is transmitted; and iii) one or more aminopsoralens; b) adding said aminopsoralen to said human serum in said container; c) photoactivating said aminopsoralens with said photoactivation device under conditions such that said aminopsoralens are capable of modifying said nucleic acid of said nucleic acid-containing vital pathogen, so that said vital pathogen is inactivated, without causing damage to said clinical sample; and d) testing said human serum for the presence of a serum analyte.
Claim 14
Dependent Claim
13 words
The method of claim 11, wherein said container is a blood collection tube.
Claim 15
Dependent Claim
10 words
The method of claim 11, wherein said aminopsoralen is 4'-aminomethyl-4,5',8-trimethylpsoralen.
Claim 16
Dependent Claim
10 words
The method of claim 11, wherein said aminopsoralen is 4'-aminomethyl-4,5'-dimethyl-8-methoxypsoralen.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-09-17 | 2000-03-18 | 2000-09-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-09-17 | 2004-03-18 | 2004-09-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-09-17 | 2008-03-18 | 2008-09-17 | $7700.00 | Window Closed / Lapsed |